Background for NeurogesX and Neuropathic Pain

Posted on June 27th, 2007 by Brian

This is a guest series from Drew Waight a graduate student at NYU. Leave him a comment if you like his analysis and maybe he’ll send another one in. I should be back in August when I’ve finally made my escape from the lab and no longer have two jobs. Until then, you can catch […]

Filed under: NeurogesX (NGSX) | 3 Comments »

NeurogesX’s Pipeline

Posted on June 29th, 2007 by Brian

This is a continuation of the guest series by Drew Waight analyzing NeurogesX for investment.
Last time I covered the therapeutic market area of neuropathic pain, which is NeurogesX’s major area of focus. This time I’ll be doing the due diligence on their first product candidate NGX-4010, and it’s safe to say that the entire company […]

Filed under: NeurogesX (NGSX) | 1 Comment »

NeurogesX to Buy or Not

Posted on July 2nd, 2007 by Brian

This is the third and final part of Drew Waight’s guest series evaluating NeurogesX for investment. Thanks to Drew! If anyone else would like to do a guest series about a recent IPO, shoot me an e-mail (it’s in the about section).
NeurogesX financial details (2006):
Burn Rate: $30million
Liquid Assets: $14million
IPO […]

Filed under: NeurogesX (NGSX) | 1 Comment »